TCGA-GU-A763-01A-11R-A32O-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 32.75295664
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.560
- MYC_TARGETS_V2+0.500
- MYC_TARGETS_V1+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- DNA_REPAIR+0.210
- FATTY_ACID_METABOLISM+0.210
- ADIPOGENESIS+0.190
- XENOBIOTIC_METABOLISM+0.180
- KRAS_SIGNALING_DN+0.170
- PANCREAS_BETA_CELLS+0.170
Top 10 suppressed
- MITOTIC_SPINDLE-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- PROTEIN_SECRETION-0.460
- G2M_CHECKPOINT-0.440
- HEDGEHOG_SIGNALING-0.440
- UV_RESPONSE_DN-0.440
- INFLAMMATORY_RESPONSE-0.400
- ANGIOGENESIS-0.390
- IL6_JAK_STAT3_SIGNALING-0.370
- TNFA_SIGNALING_VIA_NFKB-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-MT-A67A-01A-11R-A30B-07 | — | — | 0.934 |
| 2 | TCGA-A2-A3XV-01A-21R-A239-07 | — | B | 0.876 |
| 3 | MDT-AP-1302 | Med | Medulloblastoma | 0.875 |
| 4 | fa9f3cc6-06eb-4cfd-8f85-9d13df39d11e | — | — | 0.866 |
| 5 | 79e77cb6-d567-4e9b-99df-e38e6e05d72e | — | — | 0.863 |
| 6 | SRR1313092 | — | B | 0.863 |
| 7 | TCGA-XF-AAN1-01A-31R-A42T-07 | — | — | 0.846 |
| 8 | SRR2016956 | — | — | 0.844 |
| 9 | TCGA-LL-A6FP-01A-11R-A31O-07 | — | B | 0.843 |
| 10 | 4245e942-3439-4e98-9733-b0b8ac25ad56 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.560 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.500 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.190 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.170 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.040 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |